Overview

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (Factor XI Hemodialysis Study) (MK-2060-007)

Status:
Recruiting
Trial end date:
2023-04-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.